This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Aleafia Health Valuation

Is AH undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of AH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate AH's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate AH's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AH?

Key metric: As AH is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for AH. This is calculated by dividing AH's market cap by their current revenue.
What is AH's PS Ratio?
PS Ratio	0.2x
Sales	CA$42.85m
Market Cap	CA$8.07m

AH key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.3x
Enterprise Value/EBITDA	-4.6x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does AH's PS Ratio compare to its peers?

The above table shows the PS ratio for AH vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	0.4x
SPR Sproutly Canada	n/a	n/a	CA$7.6m
MBIO MindBio Therapeutics	n/a	n/a	CA$3.4m
SLNG SLANG Worldwide	0.04x	n/a	CA$1.1m
CTX Crescita Therapeutics	0.7x	n/a	CA$11.9m
AH Aleafia Health	0.2x	n/a	CA$8.1m

Price-To-Sales vs Peers: AH is good value based on its Price-To-Sales Ratio (0.2x) compared to the peer average (5.7x).

Price to Sales Ratio vs Industry

How does AH's PS Ratio compare vs other companies in the CA Pharmaceuticals Industry?

23 Companies	Price / Sales	Estimated Growth	Market Cap
Industry Avg.	0.9x	10.6%
AH Aleafia Health	0.2x	n/a	US$5.93m
AYR.A Ayr Wellness	0.2x	2.5%	US$82.15m
IAN iAnthus Capital Holdings	0.1x	n/a	US$23.79m

23 Companies		Estimated Growth	Market Cap
Industry Avg.	0.9x	53.7%
AH Aleafia Health	0.2x	n/a	US$5.93m

No more companies

Price-To-Sales vs Industry: AH is good value based on its Price-To-Sales Ratio (0.2x) compared to the Canadian Pharmaceuticals industry average (0.9x).

Price to Sales Ratio vs Fair Ratio

What is AH's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AH PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.2x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate AH's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Cresco Labs

CA$744.9m

Cresco Labs Inc., together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States.

CA$1.72

3.0%

-25.2%

Decibel Cannabis

CA$27.7m

An integrated cannabis company, engages in the cannabis cultivation, processing, and sale of cannabis flower products in Canada.

CA$0.065

-50.0%

Bausch Health Companies

US$2.9b

Operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally.

BHC

US$11.39

-0.8%

18.8%